Vedolizumab-induced acute pancreatitis: the first reported clinical case. (5th January 2018)

• Record Type: Journal Article
• Authors: Picardo, Sherman; So, Kenji; Venugopal, Kannan; Chin, Marcus
• Is Part Of: BMJ case reports. Volume 2018
• Publication Date: 2018-01-05
• Subjects: contraindications and precautions -- gastrointestinal system -- inflammatory bowel disease; Medicine -- Case studies -- Periodicals; 610.5
• DOI: 10.1136/bcr-2017-222554
• Languages: English
• ISSNs: 1757-790X

Abstract

Abstract : Drug-induced acute pancreatitis (DIAP) is a rare, but clinically significant diagnosis. Vedolizumab, an α4 β7 integrin inhibitor, which was approved in 2015 for treatment of moderate to severe inflammatory bowel disease, is a well-tolerated medication with a favourable safety profile and minimal serious adverse events in premarketing clinical trials. We present the first reported case of acute pancreatitis directly attributable to vedolizumab.